Selected research
Industry Research
Enzalutamide Drugs Industry Research Report 2026
Market perspective
The global Enzalutamide Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Enzalutamide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Enzalutamide Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Enzalutamide Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Enzalutamide Drugs include Yichang Humanwell Pharmaceutical, Shenyang Hongqi Pharmaceutical, PuraCap Pharmaceuticals, Qilu Pharmaceutical, Kelun Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Zydus, Sun Pharma and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Enzalutamide Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Enzalutamide Drugs Market by Company
Yichang Humanwell Pharmaceutical
Shenyang Hongqi Pharmaceutical
PuraCap Pharmaceuticals
Qilu Pharmaceutical
Kelun Pharmaceutical
Jiangsu Hansoh Pharmaceutical
Zydus
Sun Pharma
Pfizer
Intas Pharmaceuticals
Glenmark Pharma
Beacon pharma
BDR Pharma
Astellas Pharma
Arechar Healthcare
Aprazer Healthcare Pharma
Abbott Laboratories
Enzalutamide Drugs Segment by Type
Tablets
Capsules
Enzalutamide Drugs Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Enzalutamide Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Enzalutamide Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Enzalutamide Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Enzalutamide Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Enzalutamide Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Enzalutamide Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Enzalutamide Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablets
- Capsules
Applications
- Hospital and Clinic
- Retail Pharmacies
- Other
Companies covered
- Yichang Humanwell Pharmaceutical
- Shenyang Hongqi Pharmaceutical
- PuraCap Pharmaceuticals
- Qilu Pharmaceutical
- Kelun Pharmaceutical
- Jiangsu Hansoh Pharmaceutical
- Zydus
- Sun Pharma
- Pfizer
- Intas Pharmaceuticals
- Glenmark Pharma
- Beacon pharma
- BDR Pharma
- Astellas Pharma
- Arechar Healthcare
- Aprazer Healthcare Pharma
- Abbott Laboratories
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Enzalutamide Drugs Market Size (2021-2032)
- 2.2.2 Global Enzalutamide Drugs Sales (2021-2032)
- 2.2.3 Global Enzalutamide Drugs Market Average Price (2021-2032)
- 2.3 Enzalutamide Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tablets
- 2.3.3 Capsules
- 2.4 Enzalutamide Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital and Clinic
- 2.4.3 Retail Pharmacies
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Enzalutamide Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Enzalutamide Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Enzalutamide Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Enzalutamide Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Enzalutamide Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Enzalutamide Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Enzalutamide Drugs, Product Type & Application
- 3.8 Global Manufacturers of Enzalutamide Drugs, Established Date
- 3.9 Global Enzalutamide Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yichang Humanwell Pharmaceutical
- 4.1.1 Yichang Humanwell Pharmaceutical Company Information
- 4.1.2 Yichang Humanwell Pharmaceutical Business Overview
- 4.1.3 Yichang Humanwell Pharmaceutical Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yichang Humanwell Pharmaceutical Enzalutamide Drugs Product Portfolio
- 4.1.5 Yichang Humanwell Pharmaceutical Recent Developments
- 4.2 Shenyang Hongqi Pharmaceutical
- 4.2.1 Shenyang Hongqi Pharmaceutical Company Information
- 4.2.2 Shenyang Hongqi Pharmaceutical Business Overview
- 4.2.3 Shenyang Hongqi Pharmaceutical Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shenyang Hongqi Pharmaceutical Enzalutamide Drugs Product Portfolio
- 4.2.5 Shenyang Hongqi Pharmaceutical Recent Developments
- 4.3 PuraCap Pharmaceuticals
- 4.3.1 PuraCap Pharmaceuticals Company Information
- 4.3.2 PuraCap Pharmaceuticals Business Overview
- 4.3.3 PuraCap Pharmaceuticals Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 PuraCap Pharmaceuticals Enzalutamide Drugs Product Portfolio
- 4.3.5 PuraCap Pharmaceuticals Recent Developments
- 4.4 Qilu Pharmaceutical
- 4.4.1 Qilu Pharmaceutical Company Information
- 4.4.2 Qilu Pharmaceutical Business Overview
- 4.4.3 Qilu Pharmaceutical Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Qilu Pharmaceutical Enzalutamide Drugs Product Portfolio
- 4.4.5 Qilu Pharmaceutical Recent Developments
- 4.5 Kelun Pharmaceutical
- 4.5.1 Kelun Pharmaceutical Company Information
- 4.5.2 Kelun Pharmaceutical Business Overview
- 4.5.3 Kelun Pharmaceutical Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Kelun Pharmaceutical Enzalutamide Drugs Product Portfolio
- 4.5.5 Kelun Pharmaceutical Recent Developments
- 4.6 Jiangsu Hansoh Pharmaceutical
- 4.6.1 Jiangsu Hansoh Pharmaceutical Company Information
- 4.6.2 Jiangsu Hansoh Pharmaceutical Business Overview
- 4.6.3 Jiangsu Hansoh Pharmaceutical Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Jiangsu Hansoh Pharmaceutical Enzalutamide Drugs Product Portfolio
- 4.6.5 Jiangsu Hansoh Pharmaceutical Recent Developments
- 4.7 Zydus
- 4.7.1 Zydus Company Information
- 4.7.2 Zydus Business Overview
- 4.7.3 Zydus Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Zydus Enzalutamide Drugs Product Portfolio
- 4.7.5 Zydus Recent Developments
- 4.8 Sun Pharma
- 4.8.1 Sun Pharma Company Information
- 4.8.2 Sun Pharma Business Overview
- 4.8.3 Sun Pharma Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sun Pharma Enzalutamide Drugs Product Portfolio
- 4.8.5 Sun Pharma Recent Developments
- 4.9 Pfizer
- 4.9.1 Pfizer Company Information
- 4.9.2 Pfizer Business Overview
- 4.9.3 Pfizer Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Pfizer Enzalutamide Drugs Product Portfolio
- 4.9.5 Pfizer Recent Developments
- 4.10 Intas Pharmaceuticals
- 4.10.1 Intas Pharmaceuticals Company Information
- 4.10.2 Intas Pharmaceuticals Business Overview
- 4.10.3 Intas Pharmaceuticals Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Intas Pharmaceuticals Enzalutamide Drugs Product Portfolio
- 4.10.5 Intas Pharmaceuticals Recent Developments
- 4.11 Glenmark Pharma
- 4.11.1 Glenmark Pharma Company Information
- 4.11.2 Glenmark Pharma Business Overview
- 4.11.3 Glenmark Pharma Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Glenmark Pharma Enzalutamide Drugs Product Portfolio
- 4.11.5 Glenmark Pharma Recent Developments
- 4.12 Beacon pharma
- 4.12.1 Beacon pharma Company Information
- 4.12.2 Beacon pharma Business Overview
- 4.12.3 Beacon pharma Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Beacon pharma Enzalutamide Drugs Product Portfolio
- 4.12.5 Beacon pharma Recent Developments
- 4.13 BDR Pharma
- 4.13.1 BDR Pharma Company Information
- 4.13.2 BDR Pharma Business Overview
- 4.13.3 BDR Pharma Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 BDR Pharma Enzalutamide Drugs Product Portfolio
- 4.13.5 BDR Pharma Recent Developments
- 4.14 Astellas Pharma
- 4.14.1 Astellas Pharma Company Information
- 4.14.2 Astellas Pharma Business Overview
- 4.14.3 Astellas Pharma Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Astellas Pharma Enzalutamide Drugs Product Portfolio
- 4.14.5 Astellas Pharma Recent Developments
- 4.15 Arechar Healthcare
- 4.15.1 Arechar Healthcare Company Information
- 4.15.2 Arechar Healthcare Business Overview
- 4.15.3 Arechar Healthcare Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Arechar Healthcare Enzalutamide Drugs Product Portfolio
- 4.15.5 Arechar Healthcare Recent Developments
- 4.16 Aprazer Healthcare Pharma
- 4.16.1 Aprazer Healthcare Pharma Company Information
- 4.16.2 Aprazer Healthcare Pharma Business Overview
- 4.16.3 Aprazer Healthcare Pharma Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Aprazer Healthcare Pharma Enzalutamide Drugs Product Portfolio
- 4.16.5 Aprazer Healthcare Pharma Recent Developments
- 4.17 Abbott Laboratories
- 4.17.1 Abbott Laboratories Company Information
- 4.17.2 Abbott Laboratories Business Overview
- 4.17.3 Abbott Laboratories Enzalutamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Abbott Laboratories Enzalutamide Drugs Product Portfolio
- 4.17.5 Abbott Laboratories Recent Developments
5 Global Enzalutamide Drugs Market Scenario by Region
- 5.1 Global Enzalutamide Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Enzalutamide Drugs Sales by Region: 2021-2032
- 5.2.1 Global Enzalutamide Drugs Sales by Region: 2021-2026
- 5.2.2 Global Enzalutamide Drugs Sales by Region: 2027-2032
- 5.3 Global Enzalutamide Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Enzalutamide Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Enzalutamide Drugs Revenue by Region: 2027-2032
- 5.4 North America Enzalutamide Drugs Market Facts & Figures by Country
- 5.4.1 North America Enzalutamide Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Enzalutamide Drugs Sales by Country (2021-2032)
- 5.4.3 North America Enzalutamide Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Enzalutamide Drugs Market Facts & Figures by Country
- 5.5.1 Europe Enzalutamide Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Enzalutamide Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Enzalutamide Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Enzalutamide Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Enzalutamide Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Enzalutamide Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Enzalutamide Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Enzalutamide Drugs Market Facts & Figures by Country
- 5.7.1 South America Enzalutamide Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Enzalutamide Drugs Sales by Country (2021-2032)
- 5.7.3 South America Enzalutamide Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Enzalutamide Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Enzalutamide Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Enzalutamide Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Enzalutamide Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Enzalutamide Drugs Sales by Type (2021-2032)
- 6.1.1 Global Enzalutamide Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Enzalutamide Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Enzalutamide Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Enzalutamide Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Enzalutamide Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Enzalutamide Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Enzalutamide Drugs Sales by Application (2021-2032)
- 7.1.1 Global Enzalutamide Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Enzalutamide Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Enzalutamide Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Enzalutamide Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Enzalutamide Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Enzalutamide Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Enzalutamide Drugs Value Chain Analysis
- 8.1.1 Enzalutamide Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Enzalutamide Drugs Production Mode & Process
- 8.2 Enzalutamide Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Enzalutamide Drugs Distributors
- 8.2.3 Enzalutamide Drugs Customers
9 Global Enzalutamide Drugs Analyzing Market Dynamics
- 9.1 Enzalutamide Drugs Industry Trends
- 9.2 Enzalutamide Drugs Industry Drivers
- 9.3 Enzalutamide Drugs Industry Opportunities and Challenges
- 9.4 Enzalutamide Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst